任意団体JBCRG論文・出版
JBCRG03:Docetaxel 75mg/m2 followed by FEC100 mg/m2による術前化学療法 -JBCRG01,02からのreviewとbreakthrough-
柏葉 匡寛、若林 剛 、中村 清吾 、黒井 克昌、岩田 広治、大野 真司 、増田 慎三 、佐藤 信昭 、麻賀 太郎 、山本 尚人 、青儀 健二郎、佐藤 康幸 、黒住 昌史 、津田 均 、秋山 太 、戸井 雅和, Japan BreastCancer Research Group （JBCRG）
乳癌の臨床. 2007; 22(5): 372-375
Issues in the Assessment of the Pathologic Effect of Primary Systemic Therapy for Breast Cancer
Katsumasa Kuroi, Masakazu Toi, Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG)
Breast Cancer. 2006; 13(1): 38-48.
https://doi.org/10.2325/jbcs.13.38
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Katsumasa Kuroi, Masakazu Toi, Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG)
Biomedicine and Pharmacotherapy. 2005 Oct; 59 Suppl 2: S387-392.
https://doi.org/10.1016/S0753-3322(05)80085-X
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
Shinji Ohno, Masakazu Toi, Katsumasa Kuroi, Seigo Nakamura, Hiroji Iwata, Kusama M, Norikazu Masuda, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Hitoshi Tsuda, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG)
Biomedicine and Pharmacotherapy. 2005 Oct; 59 Suppl 2: S323-324.
https://doi.org/10.1016/s0753-3322(05)80063-0
Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma
Hiroji Iwata, Seigo Nakamura, Masakazu Toi, Shin E, Norikazu Masuda, Shinji Ohno, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Katsumasa Kuroi, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group (JBCRG)
Breast Cancer. 2005; 12(2): 99-103.
https://doi.org/10.2325/jbcs.12.99